BridgeBio Pharma Price to Book Ratio 2018-2026 | BBIO
Historical price to book ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The current price to book ratio for BridgeBio Pharma as of May 11, 2026 is 0.00.
| BridgeBio Pharma Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-05-11 | 64.68 | 0.00 | |
| 2026-03-31 | 74.26 | 0.00 | |
| 2025-12-31 | 76.49 | 0.00 | |
| 2025-09-30 | 51.94 | $-9.98 | -5.20 |
| 2025-06-30 | 43.18 | $-9.30 | -4.64 |
| 2025-03-31 | 34.57 | $-8.63 | -4.01 |
| 2024-12-31 | 27.44 | $-7.67 | -3.58 |
| 2024-09-30 | 25.46 | $-6.45 | -3.95 |
| 2024-06-30 | 25.33 | $-5.75 | -4.40 |
| 2024-03-31 | 30.92 | $-5.54 | -5.58 |
| 2023-12-31 | 40.37 | $-7.67 | -5.26 |
| 2023-09-30 | 26.37 | $-6.86 | -3.84 |
| 2023-06-30 | 17.20 | $-8.36 | -2.06 |
| 2023-03-31 | 16.58 | $-7.56 | -2.19 |
| 2022-12-31 | 7.62 | $-8.25 | -0.92 |
| 2022-09-30 | 9.94 | $-7.55 | -1.32 |
| 2022-06-30 | 9.08 | $-6.84 | -1.33 |
| 2022-03-31 | 10.15 | $-7.05 | -1.44 |
| 2021-12-31 | 16.68 | $-5.88 | -2.83 |
| 2021-09-30 | 46.87 | $-5.02 | -9.33 |
| 2021-06-30 | 60.96 | $-3.06 | -19.94 |
| 2021-03-31 | 61.60 | $-2.61 | -23.59 |
| 2020-12-31 | 71.11 | $0.86 | 82.22 |
| 2020-09-30 | 37.52 | $1.76 | 21.30 |
| 2020-06-30 | 32.61 | $2.66 | 12.24 |
| 2020-03-31 | 29.00 | $3.70 | 7.84 |
| 2019-12-31 | 35.05 | $3.83 | 9.15 |
| 2019-09-30 | 21.47 | $4.45 | 4.83 |
| 2019-06-30 | 26.97 | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |